ISSN: 1885-5857 Impact factor 2023 7.2
Vol. 65. Num. 6.
Pages 586-587 (June 2012)

Assessment of Renal Involvement by Cystatin C, A Forgotten Biomarker

Valoración de la afección renal mediante la cistatina C, un biomarcador olvidado

Alberto Domínguez-RodriguezaPedro Abreu-Gonzalezb
Rev Esp Cardiol. 2011;64:1182-9210.1016/j.rec.2011.08.012
José Luis Górriz Teruel, Sandra Beltrán Catalán
Rev Esp Cardiol. 2012;65:58710.1016/j.rec.2012.02.008
Jose Luis Górriz Teruel, Sandra Beltrán Catalán

Options

To the Editor,

We read with great interest the excellent article by Górriz Teruel et al.1 on renal assessment in patients with cardiovascular disease. This extensive and excellent update did not mention cystatin C (CC), a biological marker that estimates kidney function and has lately gained importance due to its role in cardiovascular risk stratification.

Chronic kidney disease is usually associated with cardiovascular disease and greatly increases the patient's risk. Recent studies have shown that even mild renal impairment is associated with high risk, hence kidney function markers are now being considered true sentinel indicators of cardiovascular risk.2

CC is a cysteine protease inhibitor protein produced by all nucleated cells and exhibits a highly stable synthesis rate. Its low molecular weight and high isoelectric point mean that the protein is almost entirely excreted by glomerular filtration. Concentrations of the protein are unaffected by age, sex, or protein intake, and there is greater sensitivity to small changes in glomerular filtration rate. Because of these characteristics, plasma CC concentrations are one of the best markers of glomerular filtration rate.3 Several recent publications report a correlation between elevated CC concentrations and the development of cardiovascular complications in patients with coronary disease.

Koenig et al.4 studied the usefulness of CC to predict future cardiovascular events in a cohort of 1033 patients who had been diagnosed with coronary disease within 3 months before inclusion. Patients with renal failure as assessed by plasma creatinine or creatinine clearance (CrCl) presented CC values in the top quintile, compared to those who had mild renal impairment or normal kidney function. No significant differences in the incidence of cardiovascular adverse events were found among patients with differing degrees of renal dysfunction as assessed by plasma creatinine (5.4% incidence of events with creatinine >106μmol/L vs 7% incidence with creatinine<106 μmol/L; P=.63) or by CrCl (7% incidence of events in patients with CrCl<60 mL/min, 9% in patients with CrCl 60-90 mL/min, and 6.3% in patients with CrCl>90mL/min; P=.1). There were significant CC-related differences in the probability of developing a cardiovascular event according to CC quintile (14% for the top quintile and 7.7%, 4.3%, 3.9%, and 5% for the remaining quintiles in descending order; P<.0001).

A Spanish study among patients with acute coronary syndrome showed that those with higher CC concentrations presented worse cardiovascular prognosis, even in the group of patients with normal estimated glomerular filtration rate, which could have implications for risk stratification in this patient group.5 Additionally, Cepeda et al.6 conducted the first study in Spain to determine the prevalence of high CC and its correlation with cardiovascular risk factors among the general population.

Based on the scientific evidence published in the literature in recent years, we believe that CC should be considered a better marker of kidney function than other common measurements (serum creatinine and glomerular filtration rate) and a practical application is likely to be found for the various clinical settings for cardiovascular diseases.

Corresponding author: adrvdg@hotmail.com

Bibliography
[1]
Górriz Teruel JL, Beltrán Catalán S..
Valoración de afección renal, disfunción renal aguda e hiperpotasemia por fármacos usados en cardiología y nefrotoxicidad por contrastes..
Rev Esp Cardiol. , (2011), 64 pp. 1182-1192
[2]
Dharnidharka VR, Kwon C, Stevens G..
Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis..
Am J Kidney Dis. , (2002), 40 pp. 221-226
[3]
Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al..
Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease..
Ann Intern Med. , (2006), 145 pp. 237-246
[4]
Koenig W, Twardella D, Brenner H, Rothenbacher D..
Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate..
Clin Chem. , (2005), 51 pp. 321-327
[5]
García Acuña JM, González-Babarro E, Grigorian Shamagian L, Peña-Gil C, Vidal Pérez R, López-Lago AM, et al..
La cistatina C aporta más información que otros parámetros de función renal en la estratificación del riesgo de los pacientes con síndrome coronario agudo..
Rev Esp Cardiol. , (2009), 62 pp. 510-519
[6]
Cepeda J, Tranche-Iparraguirre S, Marín-Iranzo R, Fernández-Rodríguez E, Riesgo-García A, García-Casas J, et al..
Cistatina C y riesgo cardiovascular en población general..
Rev Esp Cardiol. , (2010), 63 pp. 415-422
Are you a healthcare professional authorized to prescribe or dispense medications?